Dosing and Administration
For adult and adolescent patients ≥12 years of age
FREEDOM FROM DAILY DOSING
A self-injection syringe that requires no reconstitution1
≤
1
MINUTE TO
SELF-INJECT
for most people in
the clinical trial1*
2
EVERY-
2-WEEKS
DOSING1
3
CHOICES FOR
INJECTION
SITE
abdomen, thigh,
or upper arm1
- TAKHZYRO has a half-life of ~14 days; therefore, it takes ~10 weeks (ie, 6 doses) to reach steady state and ~2 weeks until 50% of TAKHZYRO leaves the body1,2
- The recommended starting dose for patients ≥12 years old is 300 mg every 2 weeks. TAKHZYRO 300 mg every 4 weeks is also effective and may be considered if the patient is well-controlled (eg, attack-free) for more than 6 months1
- Remind patients to always have acute treatment on hand and to periodically check the date to ensure it hasn't expired
All data presented are for TAKHZYRO 300 mg every 2 weeks unless otherwise indicated. *In clinical studies, the majority of patients self-administered TAKHZYRO within 10 to 60 seconds. These injection times are based on vial administration.1
For pediatric patients 2 to <12 years of age
A LOWER DOSE FOR YOUNGER PATIENTS
Age-based dosing interval of every 2 or 4 weeks.1
Remind your patients and their caregivers to always have acute treatment on hand and periodically check the date to ensure it hasn't expired.
One month is defined as 28 days.
The TAKHZYRO
prefilled syringe
TAKHZYRO is available in a single-dose, ready-to-go, prefilled syringe!1 Compared to a vial, the prefilled syringe offers:
FEWER STEPS
FEWER SUPPLIES
LESS WASTE
OnePath® will work with your patients to provide at-home self-injection training and ongoing support.
Keep patients on track
Help your patients get the most out of treatment by talking to them about the importance of taking their medication as prescribed so they can better prevent future attacks.
Support patients
with information on
self-administration
TAKHZYRO is intended for self-administration or administration by a caregiver after being trained by a healthcare professional.1 Inform patients and caregivers that pediatric patients (2 to less than 12 years) should not self-administer TAKHZYRO. In clinical studies, the majority of patients self-administered TAKHZYRO within 10 to 60 seconds.1 You can use the FDA-approved Instructions For Use information below to show patients the proper way to administer TAKHZYRO. And let patients know they can refer to supplementary injection training materials to reinforce your instructions:
FDA-approved Instructions For Use
TWO DOSING OPTIONS PROVIDE FLEXIBILITY TO HELP MEET PATIENTS' CHANGING HAE NEEDS
Total doses per month for adult and adolescent patients ≥12 years of age
Q2W DOSING
TAKHZYRO1*
2
SUBCUTANEOUS INJECTIONS
VIA PREFILLED SYRINGE
(ONE 300 MG/2ML
INJECTION EVERY 2 WEEKS)
OR IF WELL
CONTROLLED
Q2W DOSING
TAKHZYRO1*
1
SUBCUTANEOUS INJECTION
VIA PREFILLED SYRINGE
(ONE 300 MG/2ML INJECTION EVERY
4 weeks if attack free for 6 months)
C1 ESTERASE INHIBITOR (HUMAN)
7
INTRAVENOUS
INFUSIONS
(1000 IU
every 3 or 4 days)
OR
SUBCUTANEOUS
INJECTIONS
(one injection
twice weekly;
every 3 or 4 days)
ORAL PLASMA
KALLIKREIN INHIBITOR
28
CAPSULES
(ONE 150 MG CAPSULE
DAILY)
This presentation is not intended to compare the relative safety or efficacy of these treatments. Please refer to each product's full Prescribing Information.
One month is defined as 28 days. *The recommended starting dosage in patients 12 years of age and older is 300 mg every 2 weeks. A dosing interval of every 4 weeks is also effective and may be considered if the patient is well-controlled (eg, attack free) for more than 6 months.1
TWO DOSING OPTIONS BASED ON PATIENTS' AGE AND CHANGING NEEDS
Total doses per month for pediatric patients ages 2 to <12
AGES: 2 to <6 YEARS
options
options
AGES: 6 TO <12 YEARS
options
One month is defined as 28 days. *The recommended dosage in pediatric patients 2 to less than 6 years of age is 150 mg administered subcutaneously every 4 weeks.1 †The recommended starting dosage in pediatric patients 6 to less than 12 years of age is 150 mg administered subcutaneously every 2 weeks. A dosing interval of 150 mg every 4 weeks may be considered if the patient is well-controlled (eg, attack free) for more than 6 months.1
OnePath® will work with your patients to provide at-home self-injection training and ongoing support.
TAKHZYRO is the only preventive treatment for HAE attacks indicated for patients as young as 2 years of age.1-4
Keep patients on track
Help your patients get the most out of treatment by talking to them about the importance of taking their medication as prescribed so they can better prevent future attacks.
Support patients
with information on
self-administration
TAKHZYRO is intended for self-administration or administration by a caregiver after being trained by a healthcare professional.1 Inform patients and caregivers that pediatric patients (2 to less than 12 years) should not self-administer TAKHZYRO. In clinical studies, the majority of patients self-administered TAKHZYRO within 10 to 60 seconds.1 You can use the FDA-approved Instructions For Use information below to show patients the proper way to administer TAKHZYRO. And let patients know they can refer to supplementary injection training materials to reinforce your instructions:
FDA-approved Instructions For Use
TAKHZYRO Quick Start Program-get patients started on TAKHZYRO
Sebastian started TAKHZYRO after learning that his frequent HAE attacks were potentially preventable.
ENROLL YOUR PATIENTS
Explore clinical safety
See safety information established in the clinical trials.
SEE SAFETY PROFILE